Fauci Exposed – Allegedly Defended NIH Culture of Secrecy, $325M Third-Party Royalty Complex Uncovered
New documents that have come to light purportedly show then-NIH leaders Anthony Fauci and Lawrence Tabak may not have been truthful regarding third-party royalties paid before, during, and after the pandemic.
The misleading statements were allegedly made during congressional hearings that included Sen. Rand Paul (R-Ky.) and Rep. John Moolenaar (R-Mich.)
The revelations are being brought forth by OpenTheBooks, which accused Fauci of underhanded dealings, “Big-Pharma, Chinese and Russian companies, and nefarious characters from around the world all benefited by licensing tech developed at the National Institutes of Health and paid for by U.S. taxpayers.”
At the time, Tabak was the acting director of NIH and Fauci was the director of the National Institutes of Allergies and Infectious Diseases. Both of them told Republicans they could not release the names of companies paying NIH third-party royalties.
However, a lawsuit filed by OpenTheBooks in connection to a Freedom of Information Act request forced the NIH to release the information.
The documents show which companies paid NIH scientists $325 million in third-party royalties from 56,000 transactions between September 2009 and October 2020.
“In U.S. Senate hearings during 2022, Dr. Anthony Fauci refused to disclose the companies who licensed his ‘inventions’ and paid his third-party royalties. Finally, now, we know the companies paying him. They are listed below,” OpenTheBooks reported.
“Chinese government-owned pharmaceutical companies, controlled by the Chinese Communist Party (CCP), paid the National Institutes of Health (NIH) third-party royalties to license technologies developed on the U.S. taxpayer dime. One such company neighbors the Wuhan Institute of Virology, collaborates with the lab, and even paid a royalty to Douglas Lowy, a multiple-term acting director at the National Cancer Institute, a sub-institute of NIH,” the media outlet noted.
Read more at www.bizpacreview.com
